MAXCYTE INC
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
MXCT$1.30+3.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · · Year Ended December 31, | |||||||
| · · · 2023 · · 2022 | |||||||
| Revenue | | | $41,288 | | $44,261 | ||
| Cost of goods sold | | | 4,742 | | 5,098 | ||
| Gross profit | | | 36,546 | | 39,163 | ||
| | | | | | | | |
| Operating expenses: | | | | ||||
| Research and development | | | 23,817 | | 19,514 | ||
| Sales and marketing | | | 26,975 | | 18,653 | ||
| General and administrative | | | 30,068 | | 25,829 | ||
| Depreciation and amortization | | | | 3,985 | | | 2,528 |
| Total operating expenses | | | 84,845 | | 66,524 | ||
| Operating loss | | | (48,299) | | (27,361) | ||
| | | | | | | | |
| Other income and expense: | | | | ||||
| Other expense | | | | — | | | (127) |
| Interest income | | | 10,376 | | 3,917 | ||
| Total other income | | | 10,376 | | 3,790 | ||
| Provision for income taxes | | | | — | | | — |
| Net loss | | | $(37,923) | | $(23,571) | ||
| Basic and diluted net loss per share | | | $(0.37) | | $(0.23) | ||
| Weighted average shares outstanding, basic and diluted | | | 103,268,502 | | 101,702,664 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.